From Stanford to Apple, Divya Nag is contributing to some of the world’s most consequential advancements in medical technology.
At 20, Nag was a pioneer of Induced Pluripotent Stem Technology. Her company, Stem Cell Theranostics, used this technology to preserve living heart cells outside of the body and test forthcoming drugs in a petri dish. With over $20 million in funding, the company addressed one of medicine’s most pressing issues: human cells die when outside of their host, making the process of testing important drugs an expensive, risky, ethically difficult, and time-consuming challenge. With her technology, scientists are able to use disease-specific beating heart cells derived from human skin to perform the first “clinical trial in a dish”.
Nag also cofounded StartX Med, one of the world’s seminal health care accelerators. Partnering with Stanford University, Johnson and Johnson, GE, and Merek, Startx’s companies have been acquired by Apple, Twitter, Instagram, Dropbox, and Yahoo amongst many more.
Before dropping out of Stanford as a freshman, Nag led research projects for novel stem cell therapies at the Stanford Institute for Stem Cell Biology and Regenerative Medicine. She has co-authored 18 published works and was invited to speak with President Barack Obama on Women in Entrepreneurship.
Now 26, Nag is at Apple’s Special Projects division, becoming one of the tech behemoth’s youngest, most buzzed-about leaders.